Search Within

Shanu Modi

  1. "Radiology, Department of"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (24)
  3. Review (1)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Radiology, Department of (55)
  4. Solid Tumor Oncology Division (55)
  5. GSK Faculty (42)
  6. Survivorship Research (42)

More Groups

People
  1. Clifford Hudis (36)
  2. Larry Norton (22)
  3. Sujata Patil (20)
  4. Komal Jhaveri (17)
  5. Sarat Chandarlapaty (15)
  6. Diana Lake (14)

More People

Years
  1. 2024 (2)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (3)
  5. 2019 (8)
  6. 2018 (1)

More Years

Publications
  1. Cancer Research (13)
  2. Journal of Clinical Oncology (11)
  3. Clinical Cancer Research (4)
  4. Annals of Oncology (3)
  5. Clinical Breast Cancer (3)
  6. Breast Cancer Research and Treatment (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. American Society of Clinical Oncology (12)
  3. Elsevier Inc. (6)
  4. Oxford University Press (4)
  5. Nature Publishing Group (3)
  6. Springer (2)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Journal Article

    Beylergil, V.; Morris, P. G.; Smith-Jones, P. M.; Modi, S.; Solit, D.; Hudis, C. A.; Lu, Y.; O'Donoghue, J.; Lyashchenko, S. K.; Carrasquillo, J. A.; more...
    Nuclear Medicine Communications (2013)

    Fulltext@MSK | Save
  • A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
    Journal Article

    Jhaveri, K.; Miller, K.; Rosen, L.; Schneider, B.; Chap, L.; Hannah, A.; Zhong, Z.; Ma, W.; Hudis, C.; Modi, S.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Journal Article

    Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Bone scan imaging before and after intravenous bisphosphonate therapy for osseous metastases from breast cancer
    Meeting Abstract

    Van Poznak, C.; Grewal, R.; Morris, P.; Modi, S.
    Cancer Treatment Reviews (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save